Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-020-03598-2
Abstract: Introduction Glioblastoma (GBM) has a survival rate of around 2 years with aggressive current standard of care. While other tumors have responded favorably to trials combining immunotherapy and chemotherapy, GBM remains uniformly deadly with minimal… read more here.
Keywords: preclinical studies; treatment outcomes; treatment; temozolomide treatment ... See more keywords
Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2022.835273
Abstract: We have observed a drug-tolerant/persister state in a human glioblastoma (GBM) cell line after exposure to temozolomide, the standard-of-care chemotherapeutic agent for GBM. We used a multicolor lentiviral genetic barcode labeling to follow cell population… read more here.
Keywords: four genes; temozolomide treatment; heterogeneity cooperativity; persister ... See more keywords
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22105155
Abstract: The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor) and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells. Apoptosis, autophagy, necrosis, and granules in the cytoplasm were… read more here.
Keywords: pi3k; cell; temozolomide treatment; hsp27 ... See more keywords